- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
No Successor to OCM Would Disappoint
Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.
EP: 1.No Successor to OCM Would Disappoint
EP: 2.CMMI Open to Feedback, but EOM Out of the Blue
EP: 3.Some Practices That Did Not Do OCM Are Applying
EP: 4.Seven Tumor Types: Pros and Cons
EP: 5.A Model That Is Built to “Win”
EP: 6.Addressing Health Equity and Social Needs
EP: 7.Is Five Years Long Enough?
EP: 8.Changes to MEOS and Barriers to Entry
EP: 9.Small Practices and Dual Risk: Considerations and Approaches
EP: 10.Does Pooling Make Sense?
EP: 11.What Would You Change About the EOM?
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, starts the discussion of the Enhancing Oncology Model by asking panelists to reflect on the need for CMS to provide a successor to the Oncology Care Model (OCM). Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology; Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance; and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agree that practices that had invested in practice transformation under the OCM would have been extremely disappointed if there had been no successor to the OCM.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
New Research Links Gender, Racial Microaggressions to Higher Postpartum Blood Pressure
January 9th 2025Acts of discrimination, including subtle microaggressions, during pregnancy and childbirth contribute to higher maternal mortality rates, especially among Black women, and are linked to increased postpartum blood pressure, highlighting the need for improved health care interventions and racial equity in maternity care.
Read More
